Mortality markers in nosocomial Klebsiella pneumoniae bloodstream infection by Bulent Durdu et al.
Durdu et al. SpringerPlus  (2016) 5:1892 
DOI 10.1186/s40064-016-3580-8
RESEARCH
Mortality markers in nosocomial 
Klebsiella pneumoniae bloodstream infection
Bulent Durdu1*, Ismail Necati Hakyemez1, Sibel Bolukcu1, Gulay Okay1, Bilge Gultepe2 and Turan Aslan1
Abstract 
Purpose: Klebsiella pneumoniae is the most common endogen agent for nosocomial infections. In this study, mortal-
ity markers were investigated in patients with nosocomial K. pneumoniae blood stream infection (NKp BSI).
Methods: The characteristics of patients >16 years who had NKp BSI diagnosis by daily active surveillance between 
January 2012 and January 2016 were retrospectively evaluated. Patients who died until 28th day of the clinical follow 
up and those who survived until this time were statistically compared in terms of various risk factors.
Results: One hundred ninety patients were included into the study. Mortality rate was 47.9%, carbapenem resistance 
was 43.2%. Statistical analysis have shown that in presence of post-NKp BSI sepsis, septic shock, following in intensive 
care unit (ICU), meropenem resistance, kidney failure, NKp BSI secondary to pneumonia, use of invasive instruments 
such as central venous catheter (CVC), urinary catheter (UC) and mechanical ventilator (MV), colostomy, transfusion 
and hemodialysis mortality was significantly higher. In patients admitted into the hospital for neurological disorders, 
pancreaticobiliary tract (PBT) diseases and patients who have undergone endoscopic retrograde cholangiopancrea-
tography (ERCP) and patients in whom NKp BSI secondary to PBT infection mortality rate was lower.
Conclusions: Sepsis, septic shock, clinical conditions requiring ICU treatment and meropenem resistance increase 
mortality rates in NKp BSI significantly. Mortality was higher also in patients with NKp BSI secondary to pneumonia, 
in kidney failure and when invasive instruments were used. On the other hand, in patients who were admitted to the 
hospital for neurological disorders and PBT diseases mortality rate was lower.
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Currently, due to increase in surgical procedures, inten-
sive use of invasive instruments, immunosuppressive 
therapy and other similar practices incidence of health 
care associated infections (HAI) and its significance have 
increased worldwide (Kaiser et al. 2013; Kontopidou et al. 
2014; Alicino et al. 2015). BSI, either HAI or community-
acquired are among the most severe life–threatening 
infections (Alicino et  al. 2015). Enterobacteriaceae are 
among the most important HAI source (Tumbarello et al. 
2012). Within enterobacteriaceae family K. pneumoniae 
is the most common microorganism isolated as a source 
of infection in HAI (Tumbarello et  al. 2012; Ben-David 
et al. 2012; Pau et al. 2015; Vardakas et al. 2015).
In the last decade, multi drug resistance (MDR) and the 
increase in incidence of infections due to Gram negative 
bacilli producing extended spectrum β lactamase (ESBL) 
led to the intense use of carbapenem. Because of this, 
Klebsiella pneumoniae (CRKp) resistant to carbapenem 
was first reported in 1996 and since then the prevalence 
of carbapenem resistance have reached to life threaten-
ing endemic dimensions in various regions particularly 
among populations exposed to health care (Ben-David 
et  al. 2012; Gomez-Simmonds et  al. 2015). Behindhand 
discovery of novel effective antibiotics relative to increas-
ing bacterial resistance rates pose difficulty in treat-
ing infections and increases mortality rates (Chen et  al. 
2012). In studies investigating NKp BSI outcomes crude 
mortality rate was reported at a high range between 23 
and 69% (Kontopidou et al. 2014; Tumbarello et al. 2012; 
Ben-David et  al. 2012; Pau et  al. 2015; Vardakas et  al. 
2015; van Duin et al. 2014; Hoxha et al. 2016; Ulu et al. 
2015; Kang et  al. 2006; Daikos et  al. 2014; Correa et  al. 
Open Access
*Correspondence:  bulentdurdu@gmail.com 
1 Department of Infectious Diseases and Clinical Microbiology, Faculty 
of Medicine, Bezmialem Vakif University, Adnan Menderes Boulevard, 
Fatih, 34093 Istanbul, Turkey
Full list of author information is available at the end of the article
Page 2 of 9Durdu et al. SpringerPlus  (2016) 5:1892 
2013). Structure of nosocomial infections is dynamic 
and complex and usually includes multiple variables 
negatively effecting clinical outcome. Furthermore, in the 
initial period of this infection there are additional uncer-
tainties in terms of type of the causative microorganisms 
and antibiotic susceptibility. Thus, empirical antibiotic 
therapy is the most critical step in the initial period for 
combating with the infection. Minimum 2–3 days needed 
to assess the effectiveness of the antibiotic and to resolve 
uncertainties about the type of microorganisms further 
increases the importance of this critical step.
The increasing incidence of NKp BSI, limited therapeutic 
options and uncertainties in the initial period of the infec-
tion leading to higher mortality rates created a need for 
studies focusing on detecting risk factors having an impact 
on survival and investigating the effect of empirical therapy.
Worldwide there are various studies on this subject; 
however, the clinical studies demonstrating the current 
condition in our country are scarce. Thus, in our hospi-
tal we aimed to detect risk factors effecting mortality rate 
of patients with NKp BSI and to investigate the effect of 
empirical antibiotic therapy on clinical outcome.
Methods
Patients aged >16 years, who were hospitalized between 
January 1st, 2012 and January 1st, 2016 with clini-
cal features of BSI, with a period of time  >48  h passing 
after hospitalization, with K. pneumoniae growth in at 
least one hemoculture were evaluated retrospectively. 
The patient was excluded if BSI was polybacterial, if the 
patient could not be followed-up or his/her medical data 
could not be accessed. If K. pneumoniae had caused more 
than one BSI in a patient, the first episode was evaluated.
This study was done at Bezmialem Vakif University 
Medical School Hospital with 550 beds (Istanbul, Tur-
key). Daily BSI surveillance was done based on patient 
and laboratory by infectious diseases specialists and 
infection control nurses in our hospital. Patient data were 
recorded manually on surveillance forms prepared by the 
Ministry of Health.
The demographic data, cause of hospitalization, co-
morbidities, risk factors, possible sources of infection, 
sepsis, development of septic shock, type of surgical 
intervention, antimicrobial susceptibility and informa-
tion on initial empirical antibiotic use were obtained 
from surveillance forms. The dates of hemocultures 
were obtained from the electronic data system on which 
patient data were recorded.
Sepsis and septic shock were diagnosed according to 
guidelines (Vincent et al. 2013). Those patients in whom 
monitorization was considered to be indicated in the 
ICU in the first 48  h after obtaining culture samples or 
those whose monitorization at the ICU were decided to 
be continued in the first 48 h after diagnosis of BSI were 
considered as requirement for ICU.
HAI was diagnosed during daily active surveillance 
according to Centers for Disease Control and Prevention 
criteria and recorded (Sievert et  al. 2013). Possible risk 
factors were selected in light of the medical literature. 
ERCP and blood/blood product transfusion were con-
sidered as a risk factor if done in the last 5  days before 
BSI and chemotherapy (CT) if done in the last 3 weeks. 
Surgical drain, MV, CVC, UC, total parenteral nutrition 
(TPN), hemodialysis (HD) and colostomy were consid-
ered relevant if only their use were initiated before devel-
opment of BSI and were still continuing at the time of 
BSI development. Surgical interventions that were done 
in the month before BSI were classified according to sys-
tems and were recorded.
The result of antimicrobial susceptibility was consid-
ered as resistant to carbapenem (CpR) if resistance against 
meropenem or imipenem was present, and considered as 
susceptible to carbapenem if sensitive to both (CpS).
Microbiology
Hemoculture tubes (Becton–Dickinson, USA) sent to 
the microbiology laboratory of our hospital were put in 
the BACTEC FX (Becton–Dickinson, USA) device, pro-
grammed for an incubation period of 5  days. In samples 
with positive signals during this period, first a gram stain-
ing were done from the bottle, after which incubations 
were done in blood agar (Salubris, Turkey), EMB agar 
(Salubris, Turkey) and chocolate agar (Salubris, Turkey) 
at 37  °C for 18–24  h. The bacteria that had grown were 
defined with conventional methods and automated sys-
tems (VITEK® 2 Compact (BioMérieux, France), and anti-
microbial susceptibility results obtained with VITEK-2 
were evaluated according to Clinical and Laboratory 
Standards Institute (CLSI) (2013) criteria. The strains 
identified with Vitec® 2 Compact (BioMérieux, France) 
device were also examined with Vitec® MS (MALDI-TOF) 
(BioMérieux, France) device for identification and confir-
mation and were found to be K. pneumoniae. In this study, 
K. pneumoniae strains that were isolated from the same 
clinical samples of the same patient, showing similar anti-
microbial susceptibility patterns were not evaluated. The 
MIC values found for colistin were also evaluated accord-
ing to breakpoint test values of The European Committee 
on Antimicrobial Susceptibility Testing (EUCAST).
Statistical analysis
Data was analyzed using SPSS 13.0 (Chicago, IL, USA). 
Continuous variables were described as mean ± standard 
deviation and range. Percentage values were described 
without decimal. To evaluate risk factors associated 
with mortality, Pearson χ2 test, or Fisher’s exact test for 
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categorical variables and unpaired Student’s t test for 
continuous variables were performed. Bivariate logistic 
regression analysis was conducted to obtain unadjusted 
hazard ratios and revealed as (Hazard ratio (HR); 95% 
Confidence interval; P value) NKp BSI in comparison of 
both survivor and non-survivor groups. Risk factors that 
reached statistical significance (P < 0.05) using a forward 
selection process remained in the model. All tests were 
based on two-tailed tests and p < 0.05 were considered as 
significant.
Results
Two hundred ant two patients were included in this 
study. Seven patients were excluded as they were referred 
to other centers due to various causes and could not be 
followed-up, and five patients were excluded due to isola-
tion of multiple agents. Findings, p values, hazards ratios 
and confidence intervals are summarized at Tables  1 
and 2. One hundred and fourteen patients (59.8%) were 
males and 76 (40.2%) were females. Age distribution 
was between 20 and 93  years, and mean age was 62.71 
(±16.4) years. The mean age of males was 60.89 (±16.18) 
years, and 65.42 (±16.46) years in females. The sections 
that the patients were hospitalized were as follows; 63.2% 
at the ICU, 21.6% at internal medicine wards, 15.2% in 
surgical wards. The number of patients who died until the 
28th day was 91 (47.9%), and the number of those surviv-
ing was 99 (52.1%). When mortality rates were evaluated 
according to sections, 63.3% died at the ICU, 29.3% died 
at internal medicine sections and 10.3% died at surgical 
wards. The mean age of patients that died until the 28th 
day was 64.91 (±15.54) years and the mean age of those 
surviving was 60.67 (±14.94) years. The range of hospital 
stay before development of BSI was 3–122  days, with a 
mean of 27.82 (±26.85) days in those who died and 20.65 
(±19.57) days in hose who survived. The time interval 
after diagnosis of BSI till discharge was between 0 and 
193 days, with a mean duration of 12.81 (±10.8) days in 
who had died, and 33.15 (±28.62) days in those who sur-
vived (Table 1).
The number of patients in whom sepsis developed 
was 167 (87.9%), and the number of patients with septic 
shock was 105 (55.3%). Mortality was significantly higher 
in those in whom sepsis and septic shock had developed. 
Mortality rates at the 28th day of patients for whom ICU 
care was indicated in the first 24 h after BSI or in those 
whose requirement for ICU care continued were signifi-
cantly higher (Table 1).
Rates of UC, CVC and MV use were 75.1, 70.9 and 
66.1%, respectively. Mortality rates were significantly 
higher in those in whom UC, CVC and MV were used. 
Mortality rates were significantly higher in patients in 
whom hemodialysis, colostomy and blood/blood product 
transfusions were administered, while mortality was 
lower in patients in whom ERCP was done (Table 1).
The most frequent cause was central line associated 
BSI (CLABSI) (29.5%), and the second most frequent 
cause was pneumonia (22.6%) among primary infec-
tion sources that cause NKp BSI. Other possible causes 
include PBT infections (18.4%), primary BSI (10.5%), sur-
gical area infection (SAI) (10%), urinary tract infections 
(UTI) (6.8%) and soft tissue infections (STI) (2.1%). All 
of the patients in whom possible BSI source was pneu-
monia were those that received MV support in the ICU 
and mortality was significantly high in this group. On the 
other hand, mortality was lower in patients in whom the 
possible source was PBT infections. A significant differ-
ence was not observed in others (Table 1).
Among diseases that required hospitalization, most 
prevalent was malignancy (33.7%), followed by acute res-
piratory failure (25.3%). Other disorders included PBT 
infections (16.8%), neurological disorders (16.8%), pneu-
monia (15.8%), acute abdominal pain (11.1%), trauma 
(9.5%), acute renal failure (ARF) (9.5%), cardiac disor-
ders (8.9%), sepsis (7.4%), UTI (4.2%) and chronic hepatic 
diseases (3.7%). Mortality was high in patients in whom 
the cause of hospitalization was ARF, while it was lower 
in those with PBT infection and neurological disorders. 
Mortality on the 28th day was high only in the presence 
of CRF among co-morbidities (Table 1).
43.7% of the patients had undergone surgical inter-
vention before BSI. Types of surgery included gastroin-
testinal system (GIS) (14.7%), musculoskeletal system 
(10.5%), central nervous system (CNS) (7.9%), genitou-
rinary system (GUS) (6.8%), PBT and hepatic surgery 
(6.3%), thoracic surgery (2.1%) and cardiovascular sur-
gery (CVS) (1.1%), in descending order of frequency. A 
significant association between mortality on the 28th day 
was not observed in patients who had or had not under-
gone surgery before BSI. Also, a significant association 
between type of surgery and mortality on the 28th day 
was not observed (Table 1).
Resistance rates of 190 K. pneumoniae strains accord-
ing to CLSI breakpoint values were as follows: tigecycline 
(TGC) 23.2%, trimethoprim-sulfamethoxazole (TMP-
SXT) (39.5%), meropenem (MEM) 41.6%, gentamicin 
(GM) (46.8%), amikacin (AK) (53.7%), levofloxacin (LEV) 
(68.4%), ciprofloxacin (CIP) (70.0%), tetracyclin (TE) 
(73.2%), piperacillin-tazobactam (TZP) (74.2%), cefop-
erazone-sulbactam (CES) (77.4%), ceftazidim (CAZ) 
(89.5%), cefepime (FEP) (90.5%), sulbactam-ampicillin 
(SAM) (92.6%). Although breakpoint values suggested 
by VITEC II for colistin (CS) was not approved by the 
US Food and Drug Administration (FDA), 10% resist-
ance was observed, while resistance was not found with 
EUCAST breakpoint values. When the association of 
Page 4 of 9Durdu et al. SpringerPlus  (2016) 5:1892 
Table 1 Clinical variables and relationship with day 28th mortality
Variable Died (91) Living (99) P value HR (CI)
N % N %
Demographic data
 Mean age 64.91 ± 15.54 60.67 ± 14.94 0.074
 Hospital stay before BSI 27.82 ± 26.85 20.65 ± 19.57 0.085
 Hospital stay after BSI 12.81 ± 10.8 33.15 ± 28.62 0.0005
 Male sex 56 61.5 58 58.6 0.678
Infection complication
 Sepsis 91 100 76 76.8 0.0005 2.197 (1.86–2.59)
 Septic shock 81 89 24 24.2 0.0005 25.31 (11.35–56.43)
 Need for ICU after infection 91 100 66 66.7 0.0005 2.37 (1.98–2.85 43)
BSI Source
 CLABSI 25 27.5 31 31.3
 Pneumonia 29 31.9 15 15.2 0.006 2.61 (1.29–5.29)
 Pancreaticobiliary tract 8 8.8 27 27.3 0.001 0.25 (0.11–0.6)
 Primer BSI 12 13.2 8 8.1 0.251
 SSI 10 11 9 9.1 0.810
 UTI 6 6.6 7 7.1 0.896
 YDE 2 2.2 2 2 1.00
Indication of admittance into hospital
 Malignancy 28 30.8 36 36.4 0.415
 Acute respiratory failure 26 28.6 22 22.2 0.314
 Pancreaticobiliary tract infection 9 9.9 23 23.2 0.013 0.36 (0.15–0.83)
 Neurological disorder 9 9.9 23 23.2 0.019 0.15 (0.36–0.6)
 Pneumonia 17 18.7 13 13.1 0.295
 Acute abdomen 11 12.1 10 10.1 0.663
 Trauma 8 8.8 10 10.1 0.758
 Acute renal failure 13 14.3 5 5.1 0.028 3.13 (1.07–9.17)
 Cardiac disease 11 12.1 6 6.1 0.144
 Sepsis 8 8.8 6 6.1 0.422
 UTI 4 4.4 4 4 0.903
 Chronic live disease 4 4.4 3 3 0.618
Co–morbid disease
 Hypertension 45 49.5 50 50.5 0.885
 Malignancy 34 37.4 43 43.4 0.394
 Diabetes mellitus 27 29.7 25 25.3 0.495
 Neurological disorder 21 23.1 27 27.3 0.506
 Coronary artery disease 14 15.4 26 26.3 0.064
 Chronic liver failure 27 29.7 11 11.1 0.001 3.37 (1.56–7.3)
 Cardiac insufficiency 15 16.5 15 15.2 0.801
 Chronic obstructive pulmonary disease 10 11 14 14.1 0.512
 Hepatic failure 5 5.5 6 6.1 0.867
Risk factor
 Urinary catheter 76 83.5 66 66.7 0.007 2.53 (1.26–5.07)
 CVC 71 78 63 63.6 0.029 2.02 (1.06–3.86)
 Mechanic ventilation 69 75.8 56 56.6 0.005 2.4 (1.29–4.49)
 Blood and blood product transfusion 51 56 41 41.4 0.043 1.8 (1.01–3.2)
 Drainage 38 41.8 34 34.3 0.293
 Total parenteral nutrition 31 34.1 28 28.3 0.390
 ERCP 9 9.9 25 25.3 0.005 0.32 (0.14–0.74)
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antimicrobial resistance and mortality was examined, 
mortality was found to be significantly increased in the 
presence of MEM resistance, while significant changes 
were not observed in the presence of resistance to other 
antimicrobials (Table 2). CR was detected in 82 patients 
(43.2%). Mortality rate was 56.1% in the presence of CR, 
and 41.7% in the presence CS.
The rate of initiation of appropriate empirical antimi-
crobial treatment was 55.2% in general study popula-
tion, while 53.8% in patients who had died and 57.6% in 
those surviving. A statistically significant difference was 
not observed between mortality rates of patients who 
received or did not receive appropriate empirical therapy 
(Table 1).
BSI bloodstream infection; ICU intensive care units; HR hazard ratio; CI confidence interval; SSI surgical site infection; UTI urinary tract infection; SSTI skin and soft tissue 
infection; CLABSI central line-associated bloodstream infection; CVC central venous catheter; ERCP endoscopic retrograde cholangiopancreatography
Table 1 continued
Variable Died (91) Living (99) P value HR (CI)
N % N %
 Hemodialysis 20 22 9 9.1 0.013 2.81 (1.2–6.56)
 Chemotherapy 16 17.6 9 9.1 0.082
 Colostomy 12 13.2 2 2 0.002 7.36 (1.6–33.89)
Previous surgical procedure
 Gastrointestinal system 14 15.4 14 14.1 0.809
 Musculo-skeletal system 10 11 10 10.1 0.842
 Central nervous system 7 7.7 8 8.1 0.921
 Genitourinary system 4 4.4 9 9.1 0.256
 Bile ducts, liver and pancreas 8 8.8 4 4 0.236
 Thorax surgery 4 4.4 0 0 1.00
 Cardiovascular surgery 1 1.1 1 1 0.051
 Operation 41 45.1 42 42.4 0.715
 Appropriate empirical antibiotic therapy 49 53.8 57 57.6 0.662
Table 2 Relationship between antibiotic resistance and mortality
Antibiotic Died (91) Living (99) P value HR (CI)
Susceptible Susceptible
N % N %
Colistin 91 100.0 99 100.0 1.00
Tigecycline 71 78.0 75 75.8 0.734
Trimethoprim-sulfametaxazol 59 64.8 56 56.6 0.299
Meropenem 46 50.5 65 65.7 0.035 0.53 (0.29–0.95)
Imipenem 46 50.5 63 63.6 0.068
Meropenem or imipenem 46 50.5 63 63.6 0.067
Gentamicin 44 48.4 57 57.6 0.245
Amikacin 40 44.0 48 48.5 0.532
Levofloxacin 28 30.8 32 32.3 0.876
Ciprofloxacin 25 27.5 32 32.3 0.466
Tetracycline 20 22.0 31 31.3 0.190
Piperacillin-tazobactam 21 23.1 28 28.3 0.412
Cefoperazone-sulbactam 18 19.8 25 25.3 0.391
Ceftazidime 8 8.8 12 12.1 0.488
Cefepime 7 7.7 11 11.1 0.466
Ampicillin-sulbactam 7 7.7 7 7.1 1.00
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Discussion
In our study mortality rate at the 28th day was high with 
47.9%. In the literature, reported mortality rate is within 
the range 23–69% and the highest mortality rates were 
observed in patients admitted to ICU and in BSI cases 
where CRKp is the culprit agent (Kontopidou et al. 2014; 
Tumbarello et  al. 2012; Ben-David et  al. 2012; Vardakas 
et al. 2015; van Duin et al. 2014; Hoxha et al. 2016; Ulu 
et  al. 2015; Kang et  al. 2006; Daikos et  al. 2014; Correa 
et al. 2013). We concluded that mortality rate was high in 
our patients, since most of them were admitted to ICU. 
The studies on this subject are scarce in our country. In 
a 2012 study investigating K. pneumoniae infections in 
ICUs a similar mortality rate with 48% was reported (Ulu 
et al. 2015). These high rates have shown that NKp BSI is 
a global issue requiring an urgent answer.
Sepsis and septic shock was found to be associated with 
high mortality. In a Korean study septic shock was found 
to be an independent risk factor in community acquired 
infections and NKp BSI (Kang et al. 2006). In studies car-
ried out in USA, Greece and Italy mortality was found to 
be higher in patients developing septic shock after CRKp 
infection (Tumbarello et  al. 2012; Vardakas et  al. 2015; 
Daikos et  al. 2014; Capone et  al. 2013). Septic shock is 
a grave clinical condition leading to failure in maintain-
ing vital functions and loss of function. Monitorization 
of these patients is usually maintained at ICU under 
intense medical therapy and by using invasive instru-
ments. Thus, these patients are exposed to adverse effects 
of medical therapy and under risk of complications due 
to the use of invasive instruments. Furthermore, extreme 
age and concomitant diseases paving the way for devel-
opment of sepsis and septic shock make the clinical pic-
ture more severe. Unsurprisingly, these negative factors 
altogether lead to high mortality. Getting care at ICU has 
been determined as an independent risk factor related 
with high mortality rate. In a US study ICU was found 
to be associated with high mortality (Gomez-Simmonds 
et al. 2015). In a review mortality rate was reported to be 
higher in patients developing BSI during their stay at ICU 
(Petrosillo et al. 2013).
In our study, mortality was significantly higher in 
patients having NKp BSI secondary to pneumonia. Stud-
ies reported from USA, Italy, Hong Kong and Korea 
also include data supporting our results (Pau et al. 2015; 
Kang et al. 2006; Capone et al. 2013; Qureshi et al. 2012). 
Qureshi et  al. have assumed that high mortality in BSI 
secondary to pneumonia was due to the higher severity 
of underlying disease and relative difficulty in control-
ling the source of infection in pneumonia compared with 
other sources (Qureshi et  al. 2012). In a review use of 
MV was emphasized as a factor facilitating colonization 
with resistant K. pneumoniae strains and development of 
infection (Petrosillo et al. 2013). Also, in all of the patients 
with BSI secondary to pneumonia use of MV in ICU was 
the case and that may have lead to inadequate control of 
infection in these patients. Thus, in patients getting MV 
support at ICU rigorous attention is mandatory to pre-
vent pneumonia in these patients and infection control 
measures should also be checked. In case pneumonia has 
occurred, efforts for prevention of more severe infections 
such as BSI should be spent by way of early, appropriate 
treatment.
Survival was found to be higher in patients whom 
probable BSI source is PBT infection. In the reviewed 
literature there was only one study investigating the 
relationship between PBT infection and Kp BSI. In this 
Korean study, survival rate was found to be significantly 
high in patients having community-acquired Kp BSI or 
NKp BSI with PBT infection as the probable source of 
infection. Observed characteristics of patients with PBT 
infection were less co-morbidity compared to general 
population, less exposure to invasive instrument use, 
shorter hospitalization and lower rate of care at ICU. 
These were considered as the factors leading to higher 
survival rates. In line with this, survival rate was high 
also in patients who have undergone ERCP. Obstruc-
tions within the PBT may facilitate development of infec-
tion. It’s considered that easy passage from the PBT after 
ERCP performed with minimal invasiveness and use of 
prophylactic antibiotics may have facilitated infection 
control and thereby may have increased survival rate.
In patients hospitalized for ARF or in those having CRF 
as co-morbid disease but hospitalized for another disor-
der and in patients getting hemodialysis as supportive 
therapy mortality rate at Day 28 was found to be signifi-
cantly higher. In various studies presence of significant 
correlation with renal failure and mortality was empha-
sized (Vardakas et al. 2015; Qureshi et al. 2012; Corcione 
et al. 2014; Hussein et al. 2013; Dubrovskaya et al. 2013). 
In a study performed in USA use of non-optimal doses 
of nephrotoxic antibiotics such as CS was blamed in the 
relationship between renal failure and high mortality 
(Dubrovskaya et  al. 2013). The probable requirement of 
invasive supportive therapies such as hemodialysis which 
are risk factors for HAI in renal failure, immunosuppres-
sive effects of CRF and inability to use optimal dose of 
antibiotic eliminated via kidneys may cause high mortal-
ity in presence of RF.
Urinary catheter, CVC and MV use was found to be 
associated with increasing mortality. In various studies 
reported mortality rates were high in patients exposed 
to use of these types of invasive instruments (Ben-David 
et  al. 2012; Gomez-Simmonds et  al. 2015; Kang et  al. 
2006; Petrosillo et al. 2013; Hussein et al. 2013). A rela-
tionship between use of these invasive instruments and 
Page 7 of 9Durdu et al. SpringerPlus  (2016) 5:1892 
colonization of these instruments with resistant organ-
isms and development of infection was emphasized in 
some studies (Ben-David et  al. 2012; Kang et  al. 2006; 
Petrosillo et al. 2013). Use of these instruments rather in 
patients with a severe clinical picture who require care at 
ICU may also contribute to high mortality rate.
In our study, mortality was significantly high in patients 
with colostomy. In the reviewed literature there was only 
one study investigating effect of presence of colostomy 
on mortality and no significant association was detected 
(Michalopoulos et  al. 2011). The studies were rather 
focused on the effect of presence of colostomy/PEG on 
antibiotic resistance. Researchers have concluded that 
presence of colostomy/PEG didn’t cause any change in 
resistance rates (Liu et al. 2012; Chang et al. 2011; Fala-
gas et al. 2006). Further studies focused on relationship of 
this entity and mortality is needed.
In our study there was no significant relationship 
between type of surgical procedure and mortality. In a 
study, having a surgical operation within the last one 
month wasn’t found to be significantly related with mor-
tality but the type of surgery wasn’t reported (Capone 
et al. 2013). It’s assumed that pre-op assessment for co-
morbid diseases before elective surgical procedures and 
postponing or cancelling surgical operations in uncon-
trolled diseases may contribute to lack of high mortality. 
Also, shorter pre-op and post-op hospital stay may affect 
natural flora less and this may lower the risk for coloniza-
tion with resistant microorganisms and risk of infection.
Our findings have shown that, according to EUCAST 
breakpoint values colistin resistance doesn’t exist in our 
hospital; however, CR rates was high (43.2%) in accord-
ance with the literature (Alicino et  al. 2015; Vardakas 
et  al. 2015; Chen et  al. 2012; van Duin et  al. 2014; Ulu 
et  al. 2015; Hussein et  al. 2013). In a study investigated 
instrument-related infections developing during 2003–
2012 in our country and including all ICUs of 29 hospi-
tals from 10 cities CRKp resistance rate at CLABSI was 
6.3% (Leblebicioglu et  al. 2014). In two separate studies 
investigating HAI developing in ICUs during 2009–2011 
and 2012 CRKp rate was 22 and 48% respectively (Ulu 
et  al. 2015; Budak et  al. 2014). Increasing CRKp inci-
dence over the years are clearly seen in these studies and 
our CRKp rate is high in line with the data of Candevir 
et al. which is the closest study to present-time (Ulu et al. 
2015). In line with the literature, high CRKp incidence 
which is a threat in most countries has also grown in our 
country to a dimension that is posing threat. New studies 
revealing more clear data and including various regions 
are needed about this issue.
Contrary to our expectations, there was no significant 
relationship between appropriate use of empirical anti-
biotic therapy and survival. Presence of many adverse 
factors such as co-morbid diseases or negative clinical 
conditions adversely effecting survival may cancel the 
positive effects of appropriate use of empirical antibiotic 
therapy in lowering mortality rates. In similar studies it 
was reported that conformity of initial therapy with anti-
biogram test doesn’t lead to a change in survival rate of 
patients (Ben-David et  al. 2012; Pau et  al. 2015; Correa 
et al. 2013; Qureshi et al. 2012).
Our study has some limitations such as its retrospec-
tive design which doesn’t permit desired modifications in 
the design of the study. The antibiotic susceptibility tests 
were only performed with automated system because 
microbiology laboratory of our university had a work 
overload and the personnel were few. Procalcitonin and 
lactate test results were available only for few cases so 
that we didn’t mentioned about them in the paper. Since 
K. pneumoniae have different resistance profiles we used 
many different antibiotics or combinations as treatment. 
The data about the treatment was too excessive so we just 
mentioned about empirical therapy.
Conclusions
Our study has shown that mortality is high in the pres-
ence of post-NKp BSI sepsis, septic shock, ICU treat-
ment, meropenem resistance, NKp BSI secondary to 
pneumonia, kidney failure as the reason for hospitaliza-
tion and having renal failure as co-morbid disease. Fur-
thermore, mortality was also high in those requiring MV 
and hemodialysis as supportive therapy, and in pres-
ence of UC, CVC and colostomy. On the other hand, in 
patients who were admitted to the hospital for neurologi-
cal disorders, PBT diseases, in those whom PBT infec-
tions is considered as the source of BSI and in patients 
who have undergone ERCP mortality rate was lower. 
In situations leading to an increase in mortality rates rig-
orous attention is needed in following the rules for infec-
tion control measures, wide-spectrum antibiotics should 
be preferred in empirical therapy and remedial strategies 
for future should be adopted.
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